Table 1. Association of Eg5 expression with clinical characteristics and selected biological markers of BC.
| Characteristic | n | Eg5 expression(%) | Χ2 | P | |
|---|---|---|---|---|---|
| Low or no | High | ||||
| Age (years) | 0.688 | 0.749 | |||
| ≤40 | 9 | 4 (44.4) | 5 (55.6) | ||
| 40-60 | 76 | 30 (39.5) | 46 (60.5) | ||
| ≥60 | 42 | 20 (47.6) | 22 (52.4) | ||
| Tumor size (cm) | 1.760 | 0.185 | |||
| ≤2cm | 57 | 21 (36.8) | 36 (63.2) | ||
| >2cm | 70 | 34 (48.6) | 36 (51.4) | ||
| Tumor grade | 8.345 | 0.004* | |||
| I-II | 78 | 41 (52.6) | 37 (47.4) | ||
| III | 49 | 13(26. 5) | 36 (73.5) | ||
| ER | 4.701 | 0.030* | |||
| Negative | 43 | 24 (55.8) | 19 (44.2) | ||
| Positive | 84 | 30 (35.7) | 54 (64.3) | ||
| PR | 0.747 | 0.387 | |||
| Negative | 72 | 33 (45.8) | 39 (54.2) | ||
| Positive | 55 | 21 (38.2) | 34 (61.8) | ||
| Her2 | 0.181 | 0.670 | |||
| Negative | 82 | 36 (43.9) | 46 (56.1) | ||
| Positive | 45 | 18 (40.0) | 27 (60.0) | ||
| Ki67 | 7.850 | 0.005* | |||
| Low | 57 | 32 (56.1) | 25 (43.9) | ||
| High | 70 | 22 (31.4) | 48 (68.6) | ||
| Molecular classification | 9.280 | 0.026* | |||
| Luminal A | 46 | 20 (43.5) | 26 (56.5) | ||
| Luminal B | 38 | 10 (26.3) | 28 (73.7) | ||
| Her2-overexpression | 29 | 14 (48.3) | 15(51.7) | ||
| TNBC | 14 | 10 (71.4) | 4 (28.6) | ||
| N stage | 5.952 | 0.015* | |||
| N0 | 48 | 27 (56.2) | 21 (43.8) | ||
| N1+2+3 | 79 | 27 (34.2) | 52 (65.8) | ||
| TNM stage | 11.153 | 0.001* | |||
| Stage I-II | 88 | 46 (52.3) | 42 (47.7) | ||
| Stage III | 39 | 8 (20.5) | 31 (79.5) | ||
*p < 0.05